Sivu 1 alkaen 40 tuloksia
FIELD OF THE INVENTION
The present invention relates to the use of angiotensin I derivatives, including des-Aspartate angiotensin I in the treatment and/or prevention of infarction-related cardiac injuries and disorders. More particularly, the present invention contemplates a method for the
The enzyme cascade of the renin-angiotensin system (RAS) comprises a series of biochemical events and, as is well known, there are a variety of approaches for using regulatory intervention to open up treatment possibilities, for example treatment of hypertension.
Angiotensinogen, an
The enzyme cascade of the renin-angiotensin system (RAS) comprises a series of biochemical events and, as is well known, there are a variety of approaches for using regulatory intervention to open up treatment possibilities, for example treatment of hypertension.
Angiotensinogen, an
The invention relates to novel 1-(p-thienylbenzyl)imidazoles of formula (I), ##STR2##
which are potent agonists of angiotensin (1-7) receptors and, because of the production land release of the vasorelaxant, antithrombotic, and cardio-protective messengers cyclic 3',5'-guanosine monophosphate (cGMP)
The invention relates to novel 1-(p-thienylbenzyl)imidazoles of formula (I), ##STR2##
which are potent agonists of angiotensin (1-7) receptors and, because of the production hand release of the vasorelaxant, antithrombotic, and cardio-protective messengers cyclic 3',5'-guanosine monophosphate (cGMP)
FIELD OF THE INVENTION
This invention relates to novel compounds of the following formulae: ##STR1##
The invention also relates to pharmaceutical compositions comprising a compound of the invention as the active ingredient, a method of treating a physiological condition in mammals that is mediated
BACKGROUND OF THE INVENTION
Angiotensin-converting-enzyme (ACE) inhibitors have been shown to reduce morbidity and mortality in patients with chronic heart failure and systolic left ventricular dysfunction as well as in patients post myocardial infarction. (See The CONSENSUS Trial Study Group.
FIELD OF THE INVENTION
This invention relates to the use of inhibitors of the renin-angiotensin system.
BACKGROUND OF THE INVENTION
Wasting diseases may be categorised into generalised and localised wasting diseases. To deal first with generalised wasting, many disease processes can lead to
FIELD OF THE INVENTION
This invention relates to the use of inhibitors of the renin-angiotensin system.
BACKGROUND OF THE INVENTION
Wasting diseases may be categorised into generalised and localised wasting diseases. To deal first with generalised wasting, many disease processes can lead to
FIELD OF THE INVENTION
This invention relates to the use of inhibitors of the renin-angiotensin system.
BACKGROUND OF THE INVENTION
Wasting diseases may be categorised into generalised and localised wasting diseases. To deal first with generalised wasting, many disease processes can lead to
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to methods and compositions for treating fibrosis. More particularly, the invention relates to the use of angiotensin inhibitors in combination with nitric oxide stimulators to inhibit the progression of fibrosis.
2.
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to methods and compositions for treating fibrosis. More particularly, the invention relates to the use of angiotensin inhibitors in combination with nitric oxide stimulators to inhibit the progression of fibrosis.
2.
FIELD OF THE INVENTION
The present invention relates to novel fused heterocyclic compounds having potent pharmacological actions and intermediates for the preparation thereof. More particularly, the present invention relates to fused heterocyclic compounds having potent anti-hypertensive activity
TECHNICAL FIELD
This invention relates generally to pharmaceutical formulations for treating patients at elevated cardiovascular risk, and more particularly relates to dosage forms that combine a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin.
BACKGROUND
Many
FIELD OF THE INVENTION
The present invention relates to a novel combination of an ADP-receptor blocking antiplatelet drug, such as clopidogrel, and an antihypertensive drug, for example, an angiotensin II antagonist such as irbesartan, or an ACE inhibitor such as fosinopril, or a NEP/ACE inhibitor